Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel
Cabaletta Bio entered a 10-year commercial supply agreement with Cellares to manufacture its lead drug candidate rese-cel using Cellares’ automated Cell Shuttle and Cell Q platforms. The partnership is designed to enable low-cost, scalable production for thousands of patients annually with minimal capital investment, supporting a planned BLA submission next year.
Key figures
- Drug Name
- rese-cel (resecabtagene autoleucel)
- Agreement term years
- 10
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.